Fig 1.
Schema showing the time points MRI and CT images were acquired relative to when SABR treatment was given (Day 0).
Table 1.
Patient details.
Fig 2.
Percentage change in tumour volume between the 6 month, 12 month, 24 month and last follow-up CT relative to baseline CT.
Fig 3.
Baseline ADC map with tumour contour in red for patient 3 and associated histogram showing the frequency of ADC values in each MRI scan.
Table 2.
Correlation coefficients between the change in ADC measures relative to baseline MRI and the change in tumour volume from CT.
P-values ≤ 0.05 are in bold.
Fig 4.
Selected DCE maps at baseline and follow-up MRI scan 2 for patient 3, left to right: The contrast enhancement GD map (green = plateau, red = washout, blue = persistent), IRE, Tonset, Twashout and Ktrans.
The corresponding image between MRI scans has been visually selected.
Table 3.
Correlation coefficients between the change in mean DCE semi-quantitative parametric and pharmacokinetic values relative to baseline MRI and the change in tumour volume from CT.
P-values ≤ 0.05 are in bold.
Fig 5.
Scatterplots showing the change in (a) percentage washout voxels, (b) mean IRE and (c) mean Ktrans from follow-up MRI scan 2 versus (left–right) percentage tumour volume change at the 12 month and last follow-up CT.
Fig 6.
The percentage tumour voxels with each of the four characteristic contrast enhancement curve patterns.
B = baseline, F1 = follow-up MRI scan 1, F2 = follow-up MRI scan 2.